1. Centers for Disease Control and Prevention. About Mental Health. Available at https://www.cdc.gov/mentalhealth/learn/index.htm. Last accessed December 13, 2024.

2. National Institutes of Mental Health. Mental Illness: Statistics. Available at https://www.nimh.nih.gov/health/statistics/mental-illness. Last accessed December 13, 2024.

3. Substance Abuse and Mental Health Services Administration (SAMHSA). Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health. Available at https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf. Last accessed December 13, 2024.

4. Arias D, Saxena S, Verguet S. Quantifying the global burden of mental disorders and their economic value. eClinicalMedicine. 2022;54:101675.

5. U.S. Congress, Joint Economic Committee. Long-Term Trends in Deaths of Despair. Available at https://www.jec.senate.gov/public/index.cfm/republicans/2019/9/long-term-trends-in-deaths-of-despair. Last accessed December 13, 2024.

6. Curtin SC. State Suicide Rates Among Adolescents and Young Adults Aged 10-24: United States, 2000–2018. Natl Vital Stat Rep. 2020;69(11):1-10.

7. Substance Abuse and Mental Health Services Administration. Table 9, DSM-IV to DSM-5 Major Depressive Episode/Disorder Comparison. Available at https://www.ncbi.nlm.nih.gov/books/NBK519712/table/ch3.t5. Last accessed December 13, 2024.

8. World Health Organization. Mental Health and COVID-19: Early Evidence of the Pandemic's Impact. Available at https://iris.who.int/bitstream/handle/10665/352189/WHO-2019-nCoV-Sci-Brief-Mental-health-2022.1-eng.pdf?sequence=1. Last accessed December 13, 2024.

9. American Psychiatric Association. Seasonal Affective Disorder (SAD). Available at https://www.psychiatry.org/patients-families/seasonal-affective-disorder. Last accessed December 13, 2024.

10. Centers for Disease Control and Prevention. Depression Among Women. Available at https://www.cdc.gov/reproductivehealth/depression/index.htm. Last accessed December 13, 2024.

11. Bauman BL, Ko JY, Cox S, et al. Vital Signs: postpartum depressive symptoms and provider discussions about perinatal depression—United States, 2018. MMWR. 2020;69(19):575-581.

12. Centers for Disease Control and Prevention. Symptoms of Generalized Anxiety Disorder Among Adults: United States, 2019. Available at https://www.cdc.gov/nchs/data/databriefs/db378-H.pdf. Last accessed December 13, 2024.

13. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-1097.

14. Panchal N, Saunders H, Rudowitz R, Cox C. The Implications of COVID-19 for Mental Health and Substance Use. Available at https://www.kff.org/coronavirus-covid-19/issue-brief/the-implications-of-covid-19-for-mental-health-and-substance-use. Last accessed December 13, 2024.

15. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. Available at https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd-1410197717630.pdf. Last accessed December 13, 2024.

16. Singh B, Olds T, Curtis R, et al. Effectiveness of physical activity interventions for improving depression, anxiety and distress: an overview of systematic reviews. Br J Sports Med. 2023;57(18):1203-1209.

17. Cramer H, Lauche R, Langhorst J, Dobos G. Yoga for depression: a systematic review and meta-analysis. Depress Anxiety. 2013;30(11):1068-1083.

18. Lin IH, Huang CY, Chou SH, Shih CL. Efficacy of prenatal yoga in the treatment of depression and anxiety during pregnancy: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(9):5368.

19. Jiang X, Li H, Wang D, Shan L, Wang F, Kang Y. Efficacy of nondrug interventions in perinatal depression: a meta-analysis. Psychiatry Res. 2022;317:114916.

20. Wang G, Liang C, Sun G. Yoga's therapeutic effect on perinatal depression: a systematic review and meta-analysis. Psychiatr Danub. 2022;34(2):195-204.

21. Liu L, Liu C, Liu X, Yang Y. Summary of the effect of an exercise intervention on antenatal depression and the optimal program: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2023;23(1):293.

22. Guo L, Kong Z, Zhang Y. Qigong-based therapy for treating adults with major depressive disorder: a meta-analysis of randomized controlled trials. Int J Environ Res Public Health. 2019;16(5):826.

23. Lavretsky H, Alstein LL, Olmstead RE, et al. Complementary use of tai chi chih augments escitalopram treatment of geriatric depression: a randomized controlled trial. Am J Geriatr Psychiatry. 2011;19(10):839-850.

24. Lavretsky H, Milillo MM, Kilpatrick L, et al. A randomized controlled trial of tai chi chih or health education for geriatric depression. Am J Geriatr Psychiatry. 2022;30(3):392-403.

25. Liu X, Li R, Cui J, et al. The effects of tai chi and qigong exercise on psychological status in adolescents: a systematic review and meta-analysis. Front Psychol. 2021;12:746975.

26. Xu MM, Guo P, Ma QY, et al. Can acupuncture enhance therapeutic effectiveness of antidepressants and reduce adverse drug reactions in patients with depression? A systematic review and meta-analysis. J Integr Med. 2022;20(4):305-320.

27. Xu G, Xiao Q, Huang B, et al. Clinical evidence for association of acupuncture with improved major depressive disorder: a systematic review and meta-analysis of randomized control trials. Neuropsychobiology. 2023;82(1):1-13.

28. Li W, Yin P, Lao L, Xu S. Effectiveness of acupuncture used for the management of postpartum depression: a systematic review and meta-analysis. BioMed Res Int. 2019;2019:6597503.

29. Pakravan F, Salehabad NH, Karimi F, Isfahani MN. Comparative study of the effect of licorice muco-adhesive film on radiotherapy induced oral mucositis, a randomized controlled clinical trial. Gulf J Oncolog. 2021;1(37):42-47.

30. Kline JA, Fisher MA, Pettit KL, Linville CT, Beck AM. Controlled clinical trial of canine therapy versus usual care to reduce patient anxiety in the emergency department. PloS One. 2019;14(1):e0209232.

31. Ein N, Li L, Vickers K. The effect of pet therapy on the physiological and subjective stress response: a meta-analysis. Stress Health J Int Soc Investig Stress. 2018;34(4):477-489.

32. Blomdahl C, Guregård S, Rusner M, Wijk H. A manual-based phenomenological art therapy for individuals diagnosed with moderate to severe depression (PATd): a randomized controlled study. Psychiatr Rehabil J. 2018;41(3):169-182.

33. Ciasca EC, Ferreira RC, Santana CLA, et al. Art therapy as an adjuvant treatment for depression in elderly women: a randomized controlled trial. Rev Bras Psiquiatr Sao Paulo Braz 1999. 2018;40(3):256-263.

34. Tang Q, Huang Z, Zhou H, Ye P. Effects of music therapy on depression: a meta-analysis of randomized controlled trials. PloS One. 2020;15(11):e0240862.

35. Zhao K, Bai ZG, Bo A, Chi I. A systematic review and meta-analysis of music therapy for the older adults with depression. Int J Geriatr Psychiatry. 2016;31(11):1188-1198.

36. Lu G, Jia R, Liang D, Yu J, Wu Z, Chen C. Effects of music therapy on anxiety: a meta-analysis of randomized controlled trials. Psychiatry Res. 2021;304:114137.

37. Masika GM, Yu DSF, Li PWC. Visual art therapy as a treatment option for cognitive decline among older adults: a systematic review and meta-analysis. J Adv Nurs. 2020;76(8):1892-1910.

38. Abbing A, Baars EW, de Sonneville L, Ponstein AS, Swaab H. The effectiveness of art therapy for anxiety in adult women: a randomized controlled trial. Front Psychol. 2019;10:1203.

39. Yang W jiao, Bai Y mei, Qin L, et al. The effectiveness of music therapy for postpartum depression: A systematic review and meta-analysis. Complement Ther Clin Pract. 2019;37:93-101.

40. Goldin PR, Morrison A, Jazaieri H, Brozovich F, Heimberg R, Gross JJ. Group CBT versus MBSR for social anxiety disorder: a randomized controlled trial. J Consult Clin Psychol. 2016;84(5):427-437.

41. Arch JJ, Ayers CR, Baker A, Almklov E, Dean DJ, Craske MG. Randomized clinical trial of adapted mindfulness-based stress reduction versus group cognitive behavioral therapy for heterogeneous anxiety disorders. Behav Res Ther. 2013;51(4-5):185-196.

42. Vøllestad J, Sivertsen B, Nielsen GH. Mindfulness-based stress reduction for patients with anxiety disorders: evaluation in a randomized controlled trial. Behav Res Ther. 2011;49(4):281-288.

43. Zhou X, Guo J, Lu G, et al. Effects of mindfulness-based stress reduction on anxiety symptoms in young people: a systematic review and meta-analysis. Psychiatry Res. 2020;289:113002.

44. Hoge EA, Bui E, Mete M, Dutton MA, Baker AW, Simon NM. Mindfulness-based stress reduction vs escitalopram for the treatment of adults with anxiety disorders: a randomized clinical trial. JAMA Psychiatry. 2023;80(1):13-21.

45. Reangsing C, Lauderman C, Schneider JK. Effects of mindfulness meditation intervention on depressive symptoms in emerging adults: a systematic review and meta-analysis. J Integr Complement Med. 2022;28(1):6-24.

46. Kuyken W, Warren FC, Taylor RS, et al. Efficacy of mindfulness-based cognitive therapy in prevention of depressive relapse: an individual patient data meta-analysis from randomized trials. JAMA Psychiatry. 2016;73(6):565-574.

47. Jorm AF, Morgan AJ, Hetrick SE. Relaxation for depression. Cochrane Database Syst Rev. 2008;(4):CD007142.

48. Kim HS, Kim EJ. Effects of relaxation therapy on anxiety disorders: a systematic review and meta-analysis. Arch Psychiatr Nurs. 2018;32(2):278-284.

49. Zenouzi A, Moghadam ZB, Babayanzad S, Asghari M, Rezaei E. The effect of Benson relaxation technique on stress, anxiety, and depression in pregnant women. Holist Nurs Pract. 2024;38(4):227-237.

50. Nussbaumer-Streit B, Thaler K, Chapman A, et al. Second-generation antidepressants for treatment of seasonal affective disorder. Cochrane Database Syst Rev. 2021;3(3):CD008591.

51. Lee TM, Chan CC, Paterson JG, Janzen HL, Blashko CA. Spectral properties of phototherapy for seasonal affective disorder: a meta-analysis. Acta Psychiatr Scand. 1997;96(2):117-121.

52. Donmez M, Yorguner N, Kora K, Topcuoglu V. Efficacy of bright light therapy in perinatal depression: a randomized, double-blind, placebo-controlled study. J Psychiatr Res. 2022;149:315-322.

53. Apaydin EA, Maher AR, Shanman R, et al. A systematic review of St. John's wort for major depressive disorder. Syst Rev. 2016;5(1):148.

54. Sarris J, Ravindran A, Yatham LN, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: the World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry. 2022;23(6):424-455.

55. Schulz V. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine Int J Phytother Phytopharm. 2001;8(2):152-160.

56. Qaseem A, Barry MJ, Kansagara D, Clinical Guidelines Committee of the American College of Physicians. Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the american college of physicians. Ann Intern Med. 2016;164(5):350-359.

57. Schäfer W, Wentzell N, Schink T, Haug U. Characterization of pregnancies exposed to St. John's wort and their outcomes: a claims data analysis. Reprod Toxicol Elmsford N. 2021;102:90-97.

58. Lee A, Minhas R, Matsuda N, Lam M, Ito S. The safety of St. John's wort (Hypericum perforatum) during breastfeeding. J Clin Psychiatry. 2003;64(8):966-968.

59. Dugoua JJ, Mills E, Perri D, Koren G. Safety and efficacy of St. John's wort (Hypericum) during pregnancy and lactation. Can J Clin Pharmacol J Can Pharmacol Clin. 2006;13(3):e268-e276.

60. Tóth B, Hegyi P, Lantos T, et al. The efficacy of saffron in the treatment of mild to moderate depression: a meta-analysis. Planta Med. 2019;85(1):24-31.

61. Dai L, Chen L, Wang W. Safety and efficacy of saffron (Crocus sativus L.) for treating mild to moderate depression: a systematic review and meta-analysis. J Nerv Ment Dis. 2020;208(4):269-276.

62. Lopresti AL, Smith SJ, Hood SD, Drummond PD. Efficacy of a standardised saffron extract (Affron) as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults: a randomised, double-blind, placebo-controlled study. J Psychopharmacol Oxf Engl. 2019;33(11):1415-1427.

63. Mazidi M, Katsiki N, Mikhailidis DP, Sattar N, Banach M. Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies. Eur Heart J. 2019;40(34):2870-2879.

64. Kianbakht S, Ghazavi A. Immunomodulatory effects of saffron: a randomized double-blind placebo-controlled clinical trial. Phytother Res PTR. 2011;25(12):1801-1805.

65. Mohammadzadeh-Moghadam H, Nazari SM, Shamsa A, et al. Effects of a topical saffron (Crocus sativus L) gel on erectile dysfunction in diabetics: a randomized, parallel-group, double-blind, placebo-controlled trial. J Evid-Based Complement Altern Med. 2015;20(4):283-286.

66. Modabbernia A, Sohrabi H, Nasehi AA, et al. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology (Berl). 2012;223(4):381-388.

67. Gafner S, Blumenthal M, Foster S, Cardellina JH, Khan IA, Upton R. Botanical ingredient forensics: detection of attempts to deceive commonly used analytical methods for authenticating herbal dietary and food ingredients and supplements. J Nat Prod. 2023;86(2):460-472.

68. McGuffin M, Hobbs C, Upton R, Goldberg A. American Herbal Products Association's Botanical Safety Handbook. 2nd ed. New York, NY: CRC Press, LLC; 2013.

69. Kashani L, Eslatmanesh S, Saedi N, et al. Comparison of saffron versus fluoxetine in treatment of mild to moderate postpartum depression: a double-blind, randomized clinical trial. Pharmacopsychiatry. 2017;50(2):64-68.

70. Donelli D, Antonelli M, Bellinazzi C, Gensini GF, Firenzuoli F. Effects of lavender on anxiety: a systematic review and meta-analysis. Phytomedicine Int J Phytother Phytopharm. 2019;65:153099.

71. Yap WS, Dolzhenko AV, Jalal Z, Hadi MA, Khan TM. Efficacy and safety of lavender essential oil (Silexan) capsules among patients suffering from anxiety disorders: a network meta-analysis. Sci Rep. 2019;9(1):18042.

72. Kang HJ, Nam ES, Lee Y, Kim M. How strong is the evidence for the anxiolytic efficacy of lavender?: systematic review and meta-analysis of randomized controlled trials. Asian Nurs Res. 2019;13(5):295-305.

73. Li D, Li Y, Bai X, Wang M, Yan J, Cao Y. The effects of aromatherapy on anxiety and depression in people with cancer: a systematic review and meta-analysis. Front Public Health. 2022;10:853056.

74. Araj-Khodaei M, Noorbala AA, Yarani R, et al. A double-blind, randomized pilot study for comparison of Melissa officinalis L. and Lavandula angustifolia Mill. with fluoxetine for the treatment of depression. BMC Complement Med Ther. 2020;20(1):207.

75. Firoozeei TS, Feizi A, Rezaeizadeh H, Zargaran A, Roohafza HR, Karimi M. The antidepressant effects of lavender (Lavandula angustifolia Mill.): a systematic review and meta-analysis of randomized controlled clinical trials. Complement Ther Med. 2021;59:102679.

76. Bingham LJ, Tam MM, Palmer AM, Cahill JL, Nixon RL. Contact allergy and allergic contact dermatitis caused by lavender: a retrospective study from an Australian clinic. Contact Dermatitis. 2019;81(1):37-42.

77. Yazdkhasti M, Pirak A. The effect of aromatherapy with lavender essence on severity of labor pain and duration of labor in primiparous women. Complement Ther Clin Pract. 2016;25:81-86.

78. Al-Karawi D, Al Mamoori DA, Tayyar Y. The role of curcumin administration in patients with major depressive disorder: mini meta-analysis of clinical trials. Phytother Res PTR. 2016;30(2):175-183.

79. Wang Z, Zhang Q, Huang H, Liu Z. The efficacy and acceptability of curcumin for the treatment of depression or depressive symptoms: a systematic review and meta-analysis. J Affect Disord. 2021;282:242-251.

80. Yu JJ, Pei LB, Zhang Y, Wen ZY, Yang JL. Chronic supplementation of curcumin enhances the efficacy of antidepressants in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2015;35(4):406-410.

81. Halegoua-DeMarzio D, Navarro V, Ahmad J, et al. Liver injury associated with turmeric: a growing problem: ten cases from the Drug-Induced Liver Injury Network [DILIN]. Am J Med. 2023;136(2):200-206.

82. Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZ. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. 2002;62(13):3868-3875.

83. Mitchell TM. Correspondence re: Somasundaram et al., Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res., 62: 3868-3875, 2002. Cancer Res. 2003;63(16):5165-5166; author reply 5166-5167.

84. MEDSAFE: New Zealand Medicines and Medical Devices Safety Authority. Monitoring Communication: Beware Turmeric/Curcumin Containing Products Can Interact with Warfarin. Available at https://medsafe.govt.nz/safety/EWS/2018/Turmeric.asp. Last accessed December 13, 2024.

85. Ghazizadeh J, Sadigh-Eteghad S, Marx W, et al. The effects of lemon balm (Melissa officinalis L.) on depression and anxiety in clinical trials: a systematic review and meta-analysis. Phytother Res PTR. 2021;35(12):6690-6705.

86. Scholey A, Gibbs A, Neale C, et al. Anti-stress effects of lemon balm-containing foods. Nutrients. 2014;6(11):4805-4821.

87. Bian T, Corral P, Wang Y, et al. Kava as a clinical nutrient: promises and challenges. Nutrients. 2020;12(10):3044.

88. Zhang W, Yan Y, Wu Y, et al. Medicinal herbs for the treatment of anxiety: a systematic review and network meta-analysis. Pharmacol Res. 2022;179:106204.

89. Smith K, Leiras C. The effectiveness and safety of Kava Kava for treating anxiety symptoms: a systematic review and analysis of randomized clinical trials. Complement Ther Clin Pract. 2018;33:107-117.

90. Connor KM, Payne V, Davidson JRT. Kava in generalized anxiety disorder: three placebo-controlled trials. Int Clin Psychopharmacol. 2006;21(5):249-253.

91. Li XZ, Ramzan I. Role of ethanol in kava hepatotoxicity. Phytother Res PTR. 2010;24(4):475-480.

92. Wainiqolo I, Kool B, Nosa V, Ameratunga S. Is driving under the influence of kava associated with motor vehicle crashes? A systematic review of the epidemiological literature. Aust N Z J Public Health. 2015;39(5):495-499.

93. Aporosa AS, Atkins M, Brunton R. Kava drinking in traditional settings: towards understanding effects on cognitive function. Hum Psychopharmacol. 2020;35(2):e2725.

94. Panossian A, Wikman G, Wagner H. Plant adaptogens. III. Earlier and more recent aspects and concepts on their mode of action. Phytomedicine Int J Phytother Phytopharm. 1999;6(4):287-300.

95. Remenapp A, Coyle K, Orange T, et al. Efficacy of Withania somnifera supplementation on adult's cognition and mood. J Ayurveda Integr Med. 2022;13(2):100510.

96. Cooley K, Szczurko O, Perri D, et al. Naturopathic care for anxiety: a randomized controlled trial ISRCTN78958974. PloS One. 2009;4(8):e6628.

97. Akhgarjand C, Asoudeh F, Bagheri A, et al. Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials. Phytother Res PTR. 2022;36(11):4115-4124.

98. Sharma AK, Basu I, Singh S. Efficacy and safety of ashwagandha root extract in subclinical hypothyroid patients: a double-blind, randomized placebo-controlled trial. J Altern Complement Med N Y N. 2018;24(3):243-248.

99. Stanley TB, Ferretti ML, Bonn-Miller MO, Irons JG. A double-blind, randomized, placebo-controlled test of the effects of cannabidiol on experiences of test anxiety among college students. Cannabis Cannabinoid Res. 2023;8(6):1090-1099.

100. Berger M, Li E, Rice S, et al. Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial. J Clin Psychiatry. 2022;83(5):21m14130.

101. Masataka N. Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders. Front Psychol. 2019;10:2466.

102. Appiah-Kusi E, Petros N, Wilson R, et al. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology (Berl). 2020;237(4):1121-1130.

103. Kwee CM, Baas JM, van der Flier FE, et al. Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: a randomised controlled trial. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2022;59:58-67.

104. Epidiolex (Cannabidiol) [Package Insert]. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210365Orig1s011lbl.pdf. Last accessed December 13, 2024.

105. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318(17):1708-1709.

106. Gurley BJ, Murphy TP, Gul W, Walker LA, ElSohly M. Content versus label claims in cannabidiol (CBD)-containing products obtained from commercial outlets in the state of Mississippi. J Diet Suppl. 2020;17(5):599-607.

107. U.S. Food and Drug Administration. What You Should Know About Using Cannabis, Including CBD, When Pregnant or Breastfeeding. Available at https://www.fda.gov/consumers/consumer-updates/what-you-should-know-about-using-cannabis-including-cbd-when-pregnant-or-breastfeeding. Last accessed December 13, 2024.

108. Marchand G, Masoud AT, Govindan M, et al. Birth outcomes of neonates exposed to marijuana in utero: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(1):e2145653.

109. Wymore EM, Palmer C, Wang GS, et al. Persistence of Δ-9-tetrahydrocannabinol in human breast milk. JAMA Pediatr. 2021;175(6):632-634.

110. Wu Y, Zhang L, Li S, Zhang D. Associations of dietary vitamin B1, vitamin B2, vitamin B6, and vitamin B12 with the risk of depression: a systematic review and meta-analysis. Nutr Rev. 2022;80(3):351-366.

111. Altaf R, Gonzalez I, Rubino K, Nemec EC. Folate as adjunct therapy to SSRI/SNRI for major depressive disorder: systematic review and meta-analysis. Complement Ther Med. 2021;61:102770.

112. Gibbons RD, Hur K, Lavigne JE, Mann JJ. Association between folic acid prescription fills and suicide attempts and intentional self-harm among privately insured US adults. JAMA Psychiatry. 2022;79(11):1118-1123.

113. Centers for Disease Control and Prevention . General Information About NTDs, Folic Acid, and Folate. Available at https://www.cdc.gov/ncbddd/folicacid/faqs/faqs-general-info.html. Last accessed December 13, 2024.

114. Willems FF, Boers GHJ, Blom HJ, Aengevaeren WRM, Verheugt FWA. Pharmacokinetic study on the utilisation of 5-methyltetrahydrofolate and folic acid in patients with coronary artery disease. Br J Pharmacol. 2004;141(5):825-830.

115. Okereke OI, Reynolds CF, Mischoulon D, et al. Effect of long-term vitamin D3 supplementation vs placebo on risk of depression or clinically relevant depressive symptoms and on change in mood scores: a randomized clinical trial. JAMA. 2020;324(5):471-480.

116. Vyas CM, Mischoulon D, Chang G, et al. Effects of vitamin D3 and marine omega-3 fatty acids supplementation on indicated and selective prevention of depression in older adults: results from the Clinical Center Sub-Cohort of the VITamin D and OmegA-3 TriaL (VITAL). J Clin Psychiatry. 2023;84(4):22m14629.

117. Spedding S. Vitamin D and depression: a systematic review and meta-analysis comparing studies with and without biological flaws. Nutrients. 2014;6(4):1501-1518.

118. Srifuengfung M, Srifuengfung S, Pummangura C, Pattanaseri K, Oon-Arom A, Srisurapanont M. Efficacy and acceptability of vitamin D supplements for depressed patients: a systematic review and meta-analysis of randomized controlled trials. Nutr Burbank Los Angel Cty Calif. 2023;108:111968.

119. Shaffer JA, Edmondson D, Wasson LT, et al. Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials. Psychosom Med. 2014;76(3):190-196.

120. Wang R, Xu F, Xia X, et al. The effect of vitamin D supplementation on primary depression: a meta-analysis. J Affect Disord. 2024;344:653-661.

121. Lee ARYB, Tariq A, Lau G, Tok NWK, Tam WWS, Ho CSH. Vitamin E, alpha-tocopherol, and its effects on depression and anxiety: a systematic review and meta-analysis. Nutrients. 2022;14(3):656.

122. Zhang Y, Ding J, Liang J. Associations of dietary vitamin A and beta-carotene intake with depression. a meta-analysis of observational studies. Front Nutr. 2022;9:881139.

123. Bolzetta F, Veronese N, Stubbs B, et al. The relationship between dietary vitamin k and depressive symptoms in late adulthood: a cross-sectional analysis from a large cohort study. Nutrients. 2019;11(4):787.

124. Li D, Xu W, Wu Q, Zheng H, Li Y. Ascorbic acid intake is inversely associated with prevalence of depressive symptoms in U.S. midlife women: a cross-sectional study. J Affect Disord. 2022;299:498-503.

125. Ryszewska-Pokraśniewicz B, Mach A, Skalski M, et al. Effects of magnesium supplementation on unipolar depression: a placebo-controlled study and review of the importance of dosing and magnesium status in the therapeutic response. Nutrients. 2018;10(8):1014.

126. Tarleton EK, Littenberg B, MacLean CD, Kennedy AG, Daley C. Role of magnesium supplementation in the treatment of depression: a randomized clinical trial. PloS One. 2017;12(6):e0180067.

127. Yosaee S, Clark CCT, Keshtkaran Z, Ashourpour M, Keshani P, Soltani S. Zinc in depression: from development to treatment: a comparative/dose response meta-analysis of observational studies and randomized controlled trials. Gen Hosp Psychiatry. 2022;74:110-117.

128. da Silva LEM, de Santana MLP, Costa PR de F, et al. Zinc supplementation combined with antidepressant drugs for treatment of patients with depression: a systematic review and meta-analysis. Nutr Rev. 2021;79(1):1-12.

129. Javelle F, Lampit A, Bloch W, Häussermann P, Johnson SL, Zimmer P. Effects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis. Nutr Rev. 2020;78(1):77-88.

130. Maffei ME. 5-Hydroxytryptophan (5-HTP): natural occurrence, analysis, biosynthesis, biotechnology, physiology and toxicology. Int J Mol Sci. 2020;22(1):181.

131. Galizia I, Oldani L, Macritchie K, et al. S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database Syst Rev. 2016;10(10):CD011286.

132. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010;167(8):942-948.

133. Veronese N, Stubbs B, Solmi M, Ajnakina O, Carvalho AF, Maggi S. Acetyl-L-carnitine supplementation and the treatment of depressive symptoms: a systematic review and meta-analysis. Psychosom Med. 2018;80(2):154-159.

134. Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet. 2003;42(11):941-967.

135. Boonstra E, De Kleijn R, Colzato LS, Alkemade A, Forstmann BU, Nieuwenhuis S. Neurotransmitters as food supplements: the effects of GABA on brain and behavior. Front Psychol. 2015;6.